Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
We previously reported that glucagon-like peptide-1 (GLP-1) appearance in the portal vein facilitates hepatic vagal afferent activity, and this further augments reflexively the pancreatic vagal efferents in anesthetized rats, suggesting a neuroincretin effect of GLP-1. To determine whether the GLP-1-induced vagal pathways lead to a neuronal-mediated component (NMC) of insulin secretion, we infused GLP-1 at a physiological or pharmacological dose (1 or 3 pmol·kg−1·min−1, respectively) into the portal vein in conscious rats with selective hepatic vagotomy (Vagox) or sham operation (Sham). The experiments consisted of two sequential 10-min intraportal infusions (P1 and P2): glucose at a physiological rate (56 μmol·kg−1·min−1) in P1 and the glucose plus GLP-1 or vehicle in P2. Under arterial isoglycemia across the groups, the physiological GLP-1 infusion in Sham augmented promptly and markedly arterial insulin levels, approximately twofold the levels in glucose alone infusion ( P < 0.005), and insulin levels in Vagox diminished apparently ( P < 0.05). Almost 60% of the GLP-1-induced insulin secretion (AUC) in Sham met the NMC, i.e., difference between insulin secretion in Sham and Vagox, (AUC 976 ± 65 vs. 393 ± 94 pmol·min/l, respectively, P < 0.005). Intraportal pharmacological GLP-1 infusion further augmented insulin secretion in both groups, but the NMC remained in 46% (NS; Sham vs. Vagox). In contrast, “isoglycemic” intravenous GLP-1 infusion (3 pmol·kg−1·min−1) evoked an equal insulin secretion in both groups. Thus, the present results indicate that GLP-1 appearing in the portal vein evokes a powerful neuronal-mediated insulinotropic effect, suggesting the neuroincretin effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“The central role of the enteroinsular axis in meal-induced insulin secretion has attracted notice since it was known that at least more than 50% of the insulin released upon glucose ingestion was derived from gastrointestinal factors (34, 44).”
BackgroundFunctional and chemical anatomy of the afferent vagal system
Berthoud, H.-R., & Neuhuber, W. L. (2000) · Autonomic Neuroscience · doi:10.1016/s1566-0702(00)00215-0 · Cited by 1,280 · cited 1×
“First, as to the pancreatic efferent limb of the reflex pathways, it is known that the pancreatic vagal efferent innervation comes from the hepatic branch and the ventral gastric branch of the ventral trunk (the left vagus), and from the dorsal gastric branch and the celiac branch of the dorsal trunk (the right vagus)…”
BackgroundPlasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Subjects*
Perley, M. J., & Kipnis, D. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105685 · Cited by 917 · cited 1×
“The central role of the enteroinsular axis in meal-induced insulin secretion has attracted notice since it was known that at least more than 50% of the insulin released upon glucose ingestion was derived from gastrointestinal factors (34, 44).”
BackgroundPlasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 1×
“THE CLEAR DIFFERENCE between insulin secretion(s) to an oral, and that to intravenous, glucose load under isoglycemia was first coined in 1964 (13, 29).”
BackgroundNew Interpretation of Oral Glucose Tolerance
Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · cited 1×
“THE CLEAR DIFFERENCE between insulin secretion(s) to an oral, and that to intravenous, glucose load under isoglycemia was first coined in 1964 (13, 29).”
BackgroundCreutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Agostoni, E., Chinnock, J. E., Daly, M. D. B., & Murray, J. G. (1957) · The Journal of Physiology · doi:10.1113/jphysiol.1957.sp005703 · Cited by 688 · cited 2×
“In addition, the hepatic vagal branch, about three-fourths of the fibers of which are of afferent origin (1, 46), is known to be receptive to intraportal glucose levels, showing different response patterns of the afferents according to various intraportal glucose changes (37, 39).”
BackgroundResultInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432 · cited 1×
“Thus, the potential role of vagal GLP-1 reception in the hepatoportal area and/or outside the area, which leads to induction of multiple effects in addition to the present neuroincretin effect, such as gastric emptying (20, 36, 53) and glucose metabolism probably accompanied by stimulation of glucose clearance in nonh…”
BackgroundVilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Unger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371 · cited 2×
“As to the concept of the gut-toislet connections, the term " enteroinsular axis " was proposed by Unger and Eisentraut (48), referring particularly to the role of peptides of the gastrointestinal tract in the axis.”
BackgroundMerchenthaler, I. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90085-3 · Cited by 147 · cited 2×
“It is, however, known that some parts of the brain, including the medulla oblongata, remain outside the blood-brain-barrier (BBB) (30), that there are some sites binding to circulating GLP-1 and expressing GLP-1R in the CNS (43), and that circulating GLP-1 ).”
Background
Cited by
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
“(A) Evidence also suggests that GLP-1 receptors in the hepatoportal region [75] (B) and on afferent parasympathetic nerve endings in the intestinal mucosa (C) [76] may generate central nervous system signals influencing insulin secretion and metabolism.”
BackgroundAnti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“In addition, intraportal infusion of pharmacological GLP-1 further augments insulin secretion in both vagotomized and sham-operated rats with less increase in the former, whereas intravenous GLP-1 infusion results in equivalent insulin secretion in both groups [24], suggesting that GLP-1 has neuroincretin effects on i…”
BackgroundKnockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
MethodIwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02488-y · Cited by 200
Vagal mediation of GLP-1's effects on food intake and glycemia
Krieger, J.-P., Langhans, W., & Lee, S. J. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.001 · Cited by 67
Metadata
- Authors
- Nishizawa, M., Nakabayashi, H., Uehara, K., Nakagawa, A., Uchida, K., & Koya, D.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2013-08-01
- Volume
- 305
- Issue
- 3
- Pages
- E376-E387
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2124013755
- Cited by
- 63
- References
- 13
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.